Ewing Sarcoma Family Tumors

In order for our site to display correctly you will need a newer version of your web browser.

Currently we test and support the following browsers:

FireFox version 3.0 and above (Windows and Mac)
Safari version 5.0 and above (Windows and Mac)
Internet Explorer version 7.0 and above (Windows)

Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.

Research

Disease Information

Solid Tumor: Ewing Sarcoma Family Tumors

Alternate Names: Ewing's sarcoma, peripheral primitive neuroectodermal tumor, Askin tumor

Definition

Ewing sarcoma family tumors are small, round cell tumors that arise either in bone or soft tissues (extraosseous). These tumors are often referred to as "Ewing sarcoma's" or "pPNET" (peripheral primitive neuroectodermal tumor). In the past, chest wall pPNET’s were called Askin tumor. The cell of origin for this family of tumors is unknown.
Ewing sarcoma family tumors can occur at any site, but most commonly develop in the arms or legs, pelvis or chest wall. These tumors can spread to the lungs, bone and bone marrow. Pain and swelling at the sites of disease are the most common presenting symptoms. Sometimes patients may also have fever. Because these symptoms are suggestive of an infection, a delay in the diagnosis of a malignancy may occur.
More than 85 percent of Ewing sarcoma family tumors are characterized by a specific translocation between chromosomes 11 and 22. This translocation puts together pieces of two chromosomes (genetic material) that would normally not be together, and fuses two genes, FLI and EWS, creating what is called a fusion transcript. This translocation is felt to be important in why these tumors develop. In addition, the detection of this translocation in tumor samples has improved our ability to accurately diagnose these tumors.

Incidence

Ewing sarcoma family tumors are the second most common type of bone cancer in children and adolescence.
Approximately 200 new cases of this type of tumor are diagnosed in the United States per year.
Almost 50 percent of patients with Ewing family of tumors are between 10 and 20 years of age.

Influencing Factors

These tumors are very uncommon in people of African American and Asian descent.
Ewing sarcoma family of tumors are not commonly associated with other congenital diseases and there is no convincing evidence that this type of tumor is inherited.
Although a rare occurrence, Ewing sarcoma family of tumors can occur as a second malignancy, especially in patients who have received radiotherapy.

Survival Rates

About two-thirds of children with localized disease become long-term survivors.
Patients with tumors that are not easily accessible to surgery, such as primary tumors in the pelvis, have a poorer outcome.
Younger patients and those with smaller tumors tend to do better, although these factors seem to be less important when more intensive chemotherapy is used.
If the disease has spread to other parts of the body, survival rates are less than 30 percent.

Treatment Strategies

From past experience, it is clear that most patients who are treated with local therapy alone (surgery and/or radiation therapy), will have tumor recurrence, usually at a distant site. For this reason, chemotherapy has become part of the standard treatment for Ewing family of tumors. Chemotherapy kills tumor cells at the site of primary disease as well as tumor cells in other areas of the body that cannot be seen. Vincristine, cyclophosphamide, doxorubicin, etoposide and ifosfamide are the most commonly used chemotherapeutic agents.
Certain patients may also benefit from blood stem cell transplantation or an autologous bone marrow transplant. Autologous transplants use the patient's own marrow.

Current Research

Laboratory research at St. Jude focuses on finding out what abnormalities lead these tumors to develop and how new drugs may work to combat Ewing sarcoma family tumors. Better understanding of the tumor helps physicians better treat the disease.
St. Jude has conducted clinical trials involving more than 200 patients designed to improve the outcome of patients with Ewing sarcoma family of tumors. The current focus of our clinical research is test new drugs that work differently from standard chemotherapy to kill tumor cells.

The St. Jude Web site is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through this site should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your health care provider.

Print Email This Article